HaemaLogiX Overview

  • Founded
  • 2014

  • Status
  • Private

  • Employees
  • 5

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $10M

  • Investors
  • 2

HaemaLogiX General Information


Developer of a novel immuno-oncology and immune therapies designed for the treatment of hematologic malignancies and auto-immune diseases. The company is focused on the development and commercialization of monoclonal antibodies for the potential treatment of multiple myeloma and potentially other blood cancers, enabling clients to get targets that are highly specific to the cancer cells identified in blood cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 80 William Street
  • Suite 204
  • Woolloomooloo, New South Wales 2011
  • Australia

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HaemaLogiX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 08-Sep-2021 $10M 0000 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view HaemaLogiX’s complete valuation and funding history, request access »

HaemaLogiX Patents

HaemaLogiX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020900948-A0 Composition and method Inactive 27-Mar-2020
EP-3890780-A1 Method of treatment Pending 03-Dec-2018 0000000000
EP-3890780-A4 Method of treatment Pending 03-Dec-2018 0000000000
US-20220031840-A1 Method of treatment Pending 03-Dec-2018 0000000000
AU-2019392579-A1 Method of treatment Pending 03-Dec-2018 A61K39/395
To view HaemaLogiX’s complete patent history, request access »

HaemaLogiX Executive Team (5)

Name Title Board Seat Contact Info
Bryce Carmine Co-Founder, Chief Executive Officer & Chairman
Dimitra Korkidas Chief Financial Officer and Company Secretary
Rosanne Dunn Ph.D Chief Scientific Officer, Director of Vice President, Clinical Research & Product Development and Board Member
Tertia Dex Chief Manufacturing & Development Officer
Alan Liddle Co-Founder & Board Member
To view HaemaLogiX’s complete executive team members history, request access »

HaemaLogiX Board Members (4)

Name Representing Role Since
Alan Liddle HaemaLogiX Co-Founder & Board Member 000 0000
Bryce Carmine HaemaLogiX Co-Founder, Chief Executive Officer & Chairman 000 0000
Geoff Nichol Self Board Member 000 0000
John Cullity Self Board Member 000 0000
To view HaemaLogiX’s complete board members history, request access »

HaemaLogiX Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HaemaLogiX Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Platinum Asset Management Asset Manager Minority 000 0000 000000 0
Cicada Innovations Accelerator/Incubator Minority 000 0000 000000 0
To view HaemaLogiX’s complete investors history, request access »